Actively Recruiting
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Led by Cedars-Sinai Medical Center · Updated on 2026-03-18
160
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
Sponsors
C
Cedars-Sinai Medical Center
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).
CONDITIONS
Official Title
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Both sexes are eligible
- Age 18-30 years with BMI 18.5-24.9 kg/m2 (younger lean group)
- Age 18-30 years with BMI 30.0-39.9 kg/m2 (younger obese group)
- Age 65 years or older with BMI 30.0-39.9 kg/m2 (older obese group)
- All races and ethnic groups
- Living in the community
- Sedentary lifestyle (1.5 hours or less of exercise per week)
- Nondiabetic with fasting plasma glucose less than 126 mg/dl, 2-hour glucose during oral glucose tolerance test less than 140 mg/dl, and HbA1c less than 6.5%
- Women of childbearing potential must be not pregnant or breastfeeding and use highly effective contraception during the study and for 30 days after
You will not qualify if you...
- Diagnosed diabetes or HbA1c greater than 6.5%, fasting plasma glucose greater than 126 mg/dl, or use of anti-diabetic medications
- Exercising more than 1.5 hours per week
- Unstable weight with more than 3% change in the last 3 months
- Neurological, musculoskeletal, or other conditions limiting physical assessment or training
- Active autoimmune or inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, lupus, or inflammatory bowel disease
- Abnormal lab results indicating impaired kidney or liver function, abnormal thyroid stimulating hormone, low hemoglobin or platelets, or abnormal blood clotting tests
- Active gastrointestinal disease, bleeding disorders, or recent gastrointestinal bleeding within 6 months
- Significant heart disease or peripheral vascular disease
- QTc prolongation over 45 milliseconds or use of medications that prolong QTc
- Pulmonary disease including chronic obstructive pulmonary disease, severe asthma, or exercise-induced asthma
- Recent blood clots or embolism
- Uncontrolled high blood pressure (systolic over 170 mmHg or diastolic over 95 mmHg)
- Smoking, excessive alcohol use, or recreational drug use (other than marijuana)
- Pregnant or breastfeeding
- Recent start of systemic hormone replacement therapy in postmenopausal women
- Previous bariatric surgery
- History of stroke with motor disability
- Recent treated cancer within 3 years (excluding basal cell carcinoma)
- Acute or chronic infections
- Use of medications that interfere with metabolic studies or senolytic agents within 6 months
- History of allergy to dasatinib, quercetin, or lidocaine
- Concurrent participation in another interventional trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
Research Team
N
Nicolas Musi, MD
CONTACT
A
Arianne Aslamy, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here